PDS Biotechnology (PDSB) Latest Cancer Clinical Results

Schwab Network

English - January 22, 2023 17:56 - 9 minutes - 66.6 MB - ★★★★★ - 23 ratings
News Commentary News Business News business news news commentary news Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Are Bonds Saying That Inflation Is A 2022 Story?

Next Episode: Walmart (WMT) Launches E-Commerce Focus With Walmart Business

PDS Biotechnology (PDSB) stock price is up over 61% this past year. PDS Biotechnology director, president, and CEO, Dr. Frank Bedu, weighs in on the latest trial results that indicated 100% clinical response for treatment of cervical cancer patients with large tumors using a combination of PDS101 with standard-of-care chemoradiotherapy. All patients had a tumor shrinkage of 60% or greater.